Parkinsons Disease Drug Market 2027 By Mechanism of Action | The Insight Partners

Parkinsons Disease Drug Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Mechanism of Action (Plastic Dopamine Agonists, Anticholinergic, MAO-B Inhibitors, Amantadine, Carbidopa-Levodopa, COMT Inhibitors, Others)

Report Code: TIPRE00017479 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Parkinsons is a brain disorder that causes shaking, difficulty in balance, and coordination. The market is expected to grow, owing to the increasing cases of Parkinsons disease, with rising aging population. Pharmaceutical firms are developing new and improved therapies for Parkinsons disease, which is driving the growth of the market.

MARKET DYNAMICS

The Parkinsons disease drug market is driving due to the geriatric population and burden of Parkinsons disease, and expected launch of many blockbuster drugs during the forecast period. However, high cost of treatment is expected to hamper the growth of the global Parkinsons disease Drug market. Moreover, recent product launches and the high number of therapeutics in product pipelines is anticipated to drive demand the growth of the market.

MARKET SCOPE

The "Parkinsons Disease Drug Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Parkinsons disease Drug market with detailed market segmentation by mechanism of action. The Parkinsons disease drug market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Parkinsons disease Drug market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The Parkinsons disease drug market is segmented based on mechanism of action. Based on mechanism of action, the market is segmented into plastic dopamine agonists, anticholinergic, MAO-B inhibitors, amantadine, carbidopa-levodopa, COMT inhibitors, and others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Parkinsons disease Drug market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Parkinsons disease drug market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Parkinsons disease drug market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely, North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social, and technological factors effecting the Parkinsons disease drug market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Parkinsons disease drug market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Parkinsons disease drug market are anticipated to have lucrative growth opportunities in the future with the rising demand for Parkinsons disease drug market in the global market. Below mentioned is the list of few companies engaged in the Parkinsons disease drug market.
The report also includes the profiles of key players in Parkinsons disease drug market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •   Merck & Co. Inc.
  •   Pfizer Inc.
  •   Impax Laboratories Inc.
  •   AbbVie Inc.
  •   Mylan NV
  •   Novartis AG
  •   Boehringer Ingelheim GmbH
  •   Teva Pharmaceuticals Industries Ltd
  •   GlaxoSmithKline PLC
  •   M Somerset Pharmaceuticals Inc.

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Parkinsons Disease Drug Market - By Mechanism of Action
1.3.2 Parkinsons Disease Drug Market - By Region
1.3.2.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. PARKINSON'S DISEASE DRUG MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. PARKINSON'S DISEASE DRUG MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. PARKINSON'S DISEASE DRUG MARKET - GLOBAL MARKET ANALYSIS
6.1. PARKINSON'S DISEASE DRUG - GLOBAL MARKET OVERVIEW
6.2. PARKINSON'S DISEASE DRUG - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. PARKINSON'S DISEASE DRUG MARKET - REVENUE AND FORECASTS TO 2027 - MECHANISM OF ACTION
7.1. OVERVIEW
7.2. MECHANISM OF ACTION MARKET FORECASTS AND ANALYSIS
7.3. PLASTIC DOPAMINE AGONISTS
7.3.1. Overview
7.3.2. Plastic Dopamine Agonists Market Forecast and Analysis
7.4. ANTICHOLINERGIC
7.4.1. Overview
7.4.2. Anticholinergic Market Forecast and Analysis
7.5. MAO-B INHIBITORS
7.5.1. Overview
7.5.2. MAO-B Inhibitors Market Forecast and Analysis
7.6. AMANTADINE
7.6.1. Overview
7.6.2. Amantadine Market Forecast and Analysis
7.7. CARBIDOPA-LEVODOPA
7.7.1. Overview
7.7.2. Carbidopa-Levodopa Market Forecast and Analysis
7.8. COMT INHIBITORS
7.8.1. Overview
7.8.2. COMT Inhibitors Market Forecast and Analysis
7.9. OTHERS
7.9.1. Overview
7.9.2. Others Market Forecast and Analysis
8. PARKINSON'S DISEASE DRUG MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1 North America Parkinsons Disease Drug Market Overview
8.1.2 North America Parkinsons Disease Drug Market Forecasts and Analysis
8.1.3 North America Parkinsons Disease Drug Market Forecasts and Analysis - By Mechanism of Action
8.1.4 North America Parkinsons Disease Drug Market Forecasts and Analysis - By Countries
8.1.4.1 United States Parkinsons Disease Drug Market
8.1.4.1.1 United States Parkinsons Disease Drug Market by Mechanism of Action
8.1.4.2 Canada Parkinsons Disease Drug Market
8.1.4.2.1 Canada Parkinsons Disease Drug Market by Mechanism of Action
8.1.4.3 Mexico Parkinsons Disease Drug Market
8.1.4.3.1 Mexico Parkinsons Disease Drug Market by Mechanism of Action
8.2. EUROPE
8.2.1 Europe Parkinsons Disease Drug Market Overview
8.2.2 Europe Parkinsons Disease Drug Market Forecasts and Analysis
8.2.3 Europe Parkinsons Disease Drug Market Forecasts and Analysis - By Mechanism of Action
8.2.4 Europe Parkinsons Disease Drug Market Forecasts and Analysis - By Countries
8.2.4.1 Germany Parkinsons Disease Drug Market
8.2.4.1.1 Germany Parkinsons Disease Drug Market by Mechanism of Action
8.2.4.2 France Parkinsons Disease Drug Market
8.2.4.2.1 France Parkinsons Disease Drug Market by Mechanism of Action
8.2.4.3 Italy Parkinsons Disease Drug Market
8.2.4.3.1 Italy Parkinsons Disease Drug Market by Mechanism of Action
8.2.4.4 Spain Parkinsons Disease Drug Market
8.2.4.4.1 Spain Parkinsons Disease Drug Market by Mechanism of Action
8.2.4.5 United Kingdom Parkinsons Disease Drug Market
8.2.4.5.1 United Kingdom Parkinsons Disease Drug Market by Mechanism of Action
8.2.4.6 Rest of Europe Parkinsons Disease Drug Market
8.2.4.6.1 Rest of Europe Parkinsons Disease Drug Market by Mechanism of Action
8.3. ASIA-PACIFIC
8.3.1 Asia-Pacific Parkinsons Disease Drug Market Overview
8.3.2 Asia-Pacific Parkinsons Disease Drug Market Forecasts and Analysis
8.3.3 Asia-Pacific Parkinsons Disease Drug Market Forecasts and Analysis - By Mechanism of Action
8.3.4 Asia-Pacific Parkinsons Disease Drug Market Forecasts and Analysis - By Countries
8.3.4.1 Australia Parkinsons Disease Drug Market
8.3.4.1.1 Australia Parkinsons Disease Drug Market by Mechanism of Action
8.3.4.2 China Parkinsons Disease Drug Market
8.3.4.2.1 China Parkinsons Disease Drug Market by Mechanism of Action
8.3.4.3 India Parkinsons Disease Drug Market
8.3.4.3.1 India Parkinsons Disease Drug Market by Mechanism of Action
8.3.4.4 Japan Parkinsons Disease Drug Market
8.3.4.4.1 Japan Parkinsons Disease Drug Market by Mechanism of Action
8.3.4.5 South Korea Parkinsons Disease Drug Market
8.3.4.5.1 South Korea Parkinsons Disease Drug Market by Mechanism of Action
8.3.4.6 Rest of Asia-Pacific Parkinsons Disease Drug Market
8.3.4.6.1 Rest of Asia-Pacific Parkinsons Disease Drug Market by Mechanism of Action
8.4. MIDDLE EAST AND AFRICA
8.4.1 Middle East and Africa Parkinsons Disease Drug Market Overview
8.4.2 Middle East and Africa Parkinsons Disease Drug Market Forecasts and Analysis
8.4.3 Middle East and Africa Parkinsons Disease Drug Market Forecasts and Analysis - By Mechanism of Action
8.4.4 Middle East and Africa Parkinsons Disease Drug Market Forecasts and Analysis - By Countries
8.4.4.1 South Africa Parkinsons Disease Drug Market
8.4.4.1.1 South Africa Parkinsons Disease Drug Market by Mechanism of Action
8.4.4.2 Saudi Arabia Parkinsons Disease Drug Market
8.4.4.2.1 Saudi Arabia Parkinsons Disease Drug Market by Mechanism of Action
8.4.4.3 U.A.E Parkinsons Disease Drug Market
8.4.4.3.1 U.A.E Parkinsons Disease Drug Market by Mechanism of Action
8.4.4.4 Rest of Middle East and Africa Parkinsons Disease Drug Market
8.4.4.4.1 Rest of Middle East and Africa Parkinsons Disease Drug Market by Mechanism of Action
8.5. SOUTH AND CENTRAL AMERICA
8.5.1 South and Central America Parkinsons Disease Drug Market Overview
8.5.2 South and Central America Parkinsons Disease Drug Market Forecasts and Analysis
8.5.3 South and Central America Parkinsons Disease Drug Market Forecasts and Analysis - By Mechanism of Action
8.5.4 South and Central America Parkinsons Disease Drug Market Forecasts and Analysis - By Countries
8.5.4.1 Brazil Parkinsons Disease Drug Market
8.5.4.1.1 Brazil Parkinsons Disease Drug Market by Mechanism of Action
8.5.4.2 Argentina Parkinsons Disease Drug Market
8.5.4.2.1 Argentina Parkinsons Disease Drug Market by Mechanism of Action
8.5.4.3 Rest of South and Central America Parkinsons Disease Drug Market
8.5.4.3.1 Rest of South and Central America Parkinsons Disease Drug Market by Mechanism of Action
9. IMPACT OF COVID-19 PANDEMIC ON GLOBAL PARKINSON'S DISEASE DRUG MARKET
9.1 North America
9.2 Europe
9.3 Asia-Pacific
9.4 Middle East and Africa
9.5 South and Central America
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. PARKINSON'S DISEASE DRUG MARKET, KEY COMPANY PROFILES
11.1. MERCK AND CO. INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. PFIZER INC.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. IMPAX LABORATORIES INC.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. ABBVIE INC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. MYLAN NV
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. NOVARTIS AG
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. BOEHRINGER INGELHEIM GMBH
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. TEVA PHARMACEUTICALS INDUSTRIES LTD
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. GLAXOSMITHKLINE PLC
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. M SOMERSET PHARMACEUTICALS INC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. Merck & Co. Inc.
2. Pfizer Inc.
3. Impax Laboratories Inc.
4. AbbVie Inc.
5. Mylan NV
6. Novartis AG
7. Boehringer Ingelheim GmbH
8. Teva Pharmaceuticals Industries Ltd
9. GlaxoSmithKline PLC
10. M Somerset Pharmaceuticals Inc.
TIPRE00017479
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking